About Neurolens
Neurolens is a Healthcare company based in Coppell (United States) founded in 2008 by Davis Corley. Neurolens has raised $126.19 million across 9 funding rounds from investors including Marshall Wace, Trinity Cap and MVM Partners. Its chief executive, as recorded, is Davis Corley. Its website neurolens.com draws about 13 thousand monthly visits. Neurolens offers products and services including Neurolenses and Neurolens Test. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include SynergEyes, Nexis Vision and Paragon Vision Sciences; 2 of its 3 listed competitors have raised funding.
Company details
Provider of prescription lenses and solution for problems related to Digital Vision Syndrome. The company has a patented Contoured Prism technology and is the first and only prescription lenses to provide comfort for the majority of adults who complain of headaches, neckshoulder pain, and eyestrain when using digital devices, reading, or doing detail work, the daily symptoms of Digital Vision Syndrome, DVS. With this technology, the company corrects eye misalignment naturally and provides comfortable vision.
- Total Equity Funding$126.19M (USD)
in 9 rounds
- Latest Funding Round$45M (USD), Debt – Conventional
Dec 2023
- InvestorsMarshall Wace
& 4 more
Products & Services of Neurolens
Neurolens offers a comprehensive portfolio of products and services, including Neurolenses and Neurolens Test.
Lenses that correct eye misalignment to alleviate symptoms.
Questionnaire and measurement for identifying eye misalignment.
Apps and channels of Neurolens
its YouTube channel Neurolens has 588 subscribers and 13 videos.
Videos from Neurolens
The most watched videos on Neurolens's YouTube channel, Neurolens (588 subscribers). Click a video to play it here.
More on Neurolens.
Funding Insights of Neurolens
Neurolens has successfully raised a total of $126.19M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $45 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $126.19M
- Total Rounds 9
- Last Round Debt – Conventional — $45M
- First Round $1M
(Oct 2014)
- Investors Count 5
All 9 funding rounds of Neurolens with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $45M | Debt – Conventional | – | – | |
| Sep 2022 | $67.64M | Series C | – | MVM | |
| Mar 2020 | $23.82M | Series B | – | – | – |
| Dec 2017 | $13.12M | Series A | – | – | – |
| Nov 2017 | $7.52M | Series B | – | – | – |
| Dec 2015 | $6.04M | Series A | – | – | – |
| Dec 2015 | $6.04M | Series B | – | – | – |
| Nov 2014 | $1M | Seed | – | – | – |
| Oct 2014 | $1M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Neurolens
Neurolens has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, Trinity Cap and MVM Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt and equipment financing are provided to growth-stage companies. | 2008 | trinitycap.com | Phoenix, United States | |
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Bluestem is recognized as a Midwest private equity company. | bluestemcapital.com | Sioux Falls, United States | ||
Industrial machinery is manufactured and distributed by Falcon-Vision since 1996. | 1996 | falcon-vision.com | Budapest, Hungary |
Investor details for Neurolens
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neurolens
1 people are tracked at Neurolens (1 in leadership).
| Name | Role | Group |
|---|---|---|
Davis Corley | Co-Founder & CEO | Leadership |
Complete people profiles for Neurolens
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neurolens
3 dated milestones of Neurolens across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Neurolens is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Debt – Conventional, of $45.0M.
Competitors of Neurolens
Neurolens has 3 listed competitors in our database, 2 of them funded. They include SynergEyes, Nexis Vision and Paragon Vision Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| synergeyes.com | 2001 | Carlsbad, United States | $48.39M | 99 | Hybrid contact lense manufacturers | |
| nexisvision.com | 2005 | Menlo Park, United States | $33.17M | Ocular lens and surface technologies for ophthalmic devices are developed. | ||
| paragonvision.com | 1976 | Gilbert, United States | 63 | Provider of eye care products like corneal reshaping products, contact lenses & others |
Detailed competitors of Neurolens
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neurolens
The website of Neurolens (neurolens.com) receives about 13.3K visits a month.
- Monthly visits13.3K
▼ 13.2% vs previous month
Websites whose visitors overlap most with Neurolens. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| revolutionehr.com | 100% | 1.5M | #11,622 | View details |
Top companies in Ophthalmology
3 companies that operate in the same segment as Neurolens (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurolens
Complete news archive for Neurolens
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurolens
Neurolens was founded in 2008 and raised its 1st funding round 6 years after it was founded.
Neurolens is headquartered in Coppell, United States. It is registered at Coppell, Texas, United States.
Davis Corley is the CEO of Neurolens, as recorded in our data. They have also founded this company.
Neurolens is a funded company, having raised a total of $126.19M across 9 funding rounds to date. The company's 1st funding round was a Series A of $1M, raised on Oct 2014.
Provider of prescription lenses and solution for problems related to Digital Vision Syndrome. The company has a patented Contoured Prism technology and is the first and only prescription lenses to provide comfort for the majority of adults who complain of headaches, neckshoulder pain, and eyestrain when using digital devices, reading, or doing detail work, the daily symptoms of Digital Vision Syndrome, DVS. With this technology, the company corrects eye misalignment naturally and provides comfortable vision.
Neurolens's top competitors include SynergEyes, Nexis Vision and Paragon Vision Sciences.
Neurolens offers Neurolenses and Neurolens Test.
Neurolens has 5 investors. Key investors include Marshall Wace, Trinity Cap, MVM Partners, Falcon-Vision, and Bluestem.